Sacituzumab govitecan: as the comparator
6 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingNCT07533123Phase 3Report a problem
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingNCT07461454Phase 3Report a problem
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingNCT06102824Phase 2Report a problem
- Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerActive, not recruitingNCT07371910Phase 3Report a problem
- P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .WithdrawnNCT05008510Phase 2Report a problem
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3Report a problem